Atamestane

Summary

Atamestane (CHEMBL2105987) is a phase-3 clinical-stage small molecule; indicated across 2 conditions including breast neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 4
• Chemistry: 298.4 Da · C20H26O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2105987
Name	Atamestane
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	57050
Molecular formula	C20H26O2
Molecular weight	298.4
InChIKey	PEPMWUSGRKINHX-TXTPUJOMSA-N

SMILES: CC1=CC(=O)C=C2[C@]1([C@H]3CC[C@]4([C@H]([C@@H]3CC2)CCC4=O)C)C

IUPAC name: (8R,9S,10S,13S,14S)-1,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-3,17-dione

Also known as: Atamestane, Atamestano, SH-489, ATAMESTANE

Patent coverage: 3,173 distinct patent families (13,891 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
breast neoplasm	3	MONDO:0021100	EFO:0003869

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE3	4

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00010322	PHASE3	TERMINATED	Toremifene With or Without Atamestane in Treating Postmenopausal Women With Metastatic Breast Cancer
NCT00044291	PHASE3	COMPLETED	Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer
NCT00097344	PHASE3	TERMINATED	The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer
NCT00267553	PHASE3	TERMINATED	Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).